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Risk factors and prognosis in children hospitalized due to
pandemic H1N1 influenza A virus infection in Ankara, Turkey*
Medine Ayşin TAŞAR1, Yıldız DALLAR1, Özge UYSAL SOYER1, Şükran YILDIRIM1, Mustafa TAŞAR2,
Fatma İnci ARIKAN1

Aim: To describe the demographic characteristics and clinical features in children with influenza A (H1N1) virus
infection and to identify risk factors for severe disease or poor prognosis. Following the first tourist-imported case in
Turkey on 16 May 2009, the influenza A (H1N1) virus has spread throughout the country.
Materials and methods: Children under 18 years of age who were hospitalized for at least 24 h with an influenza-like
illness and who had confirmed influenza A (H1N1) virus infection were included in the study. Demographic factors,
clinical signs and symptoms, laboratory results, radiographic findings, treatments, and follow-up periods were noted.
Results: During the period of October to December 2009, 126 [63.5% males, median age: 3 years (range: 0.1-9 years)]
children with cases of influenza A (H1N1) virus infection were hospitalized. Fever (95.2%), cough (84.1%), rhinorrhea
(70%), and dyspnea (63.5%) were the most common presenting symptoms. A total of 46 patients (36.4%) had chronic
underlying medical conditions, with asthma being the most common (21.4%). During hospitalization, durations
of oxygen requirement and wheezing were longer in patients with chronic respiratory disease. Duration of oxygen
requirement and tachypnea decreased if oseltamivir was initiated within 48 h (P = 0.006 and 0.033, respectively). No
risk factor was defined for hospitalization longer than 4 days.
Conclusion: In our cohort, influenza A (H1N1) virus infection did not appear to cause severe disease. Asthma was a
significant risk factor for severe disease. Delayed (>48 h) initiation of antiviral therapy might have contributed to an
increase in morbidity, which suggests the importance of timely administration of antiviral treatments.
Key words: Pandemic H1N1 influenza A, oseltamivir, prognosis, asthma

Ankara’da Pandemik İnfluenza A virüs enfeksiyon nedeniyle hastaneye yatırılan
çocuklarda risk faktörleri ve prognoz
Amaç: Türkiye’de ilk vaka 16 Mayıs 2009’ da bir turistte saptandıktan sonra influenza A (H1N1) virüsü tüm ülkeye
yayıldı. Bu çalışmanın amacı H1N1 virüs enfeksiyonlu çocuklarda demografik faktörleri, klinik özellikleri ve şiddetli
hastalık veya kötü prognoz için risk faktörlerini tanımlamaktır.
Yöntem ve gereç: İnfluenza benzeri hastalığı olan ve H1N1 enfeksiyonu doğrulanmış 18 yaş altı çocuklar çalışmaya
alındı. Demografik faktörler, şikayet ve bulgular, laboratuar sonuçları, tedavi ve izlemleri kaydedildi.
Bulgular: Ekim-Aralık 2009 döneminde, 126 çocuk H1N1 [% 63,5 erkek, yaş: 3 yıl (0,1 - 9)] enfeksiyonu nedeniyle
hastaneye yatırıldı. En sık başvuru şikayetleri ateş (% 95,2), öksürük (% 84,1), burun akıntısı (% 70), ve solunum sıkıntısı
(% 63,5) idi. Hastaların % 36,4 `ünün süregen hastalığı mevcuttu; en sık astım (% 21,4) saptandı. Hastanede yatış süresi,
oksijen ihtiyacı süresi ve hışıltı süregen akciğer hastalığı olanlarda daha uzun saptandı. Oseltamivir tedavisi ilk 48 saat
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içinde başlananlarda oksijen ihtiyacı süresi ve takipne daha az bulundu (P = 0,006 ve 0,033). Dört günden daha uzun
hastanede yatış için risk faktörü saptanmadı.
Sonuç: Bu çalışmada, H1N1 virüs enfeksiyonu şiddetli hastalık nedeni olarak saptanmadı. Astım şiddetli hastalık için
belirleyici bir etken olarak bulundu. Antiviral tedavinin geç başlanması (>48 saat) artmış hastalık riski ile beraber
olabilir; bu nedenle şiddetli hastalık riski antiviral tedavinin zamanında başlanması ile azaltılabilir.
Anahtar sözcükler: Pandemik influenza A (H1N1), oseltamivir, prognoz, astım

Introduction

Materials and methods

In late April 2009, a novel influenza virus led
to human infection in Mexico. A public health
emergency of international concern was declared by
the World Health Organization (WHO) on 25 April
2009 (1). Over the following weeks, the virus spread
rapidly to all regions of the world. Consequently,
WHO declared a phase 6 pandemic on 11 June 2009
due to evidence of community-level transmission
in multiple countries globally (2). Despite the rapid
spread of the pandemic influenza A (H1N1) virus
(1,2), most cases did not have a serious disease course.
In the United States and Canada, about 2%-5% of
people with laboratory-confirmed infection required
hospitalization (3). Between one-half and two-thirds
of hospitalized cases had comorbidities such as
asthma, other chronic respiratory diseases (CRDs),
diabetes, and autoimmune disorders (3,4). Fatalities
due to pandemic influenza A (H1N1) virus did
occur (5). Based on seasonal influenza data, children
under the age of 5 years and especially those under
the age of 2 years, as well as those with underlying
chronic conditions, are at a substantially higher risk
of hospitalization compared to older or otherwise
healthy children. Pulmonary complications such as
bronchitis or pneumonia, neurological complications
such as encephalitis or encephalopathy, and a sepsislike syndrome in neonates have been reported even
in previously healthy children (6,7).

Children under 18 years of age who were hospitalized
for at least 24 h with an influenza-like illness and who
had pandemic influenza A (H1N1) virus infection
as confirmed by a real-time reverse-transcriptase
polymerase chain reaction (RT-PCR) assay between
October and December 2009 at the Ankara Training
and Research Hospital, Ankara, Turkey, were
included in the analysis. A probable case of pandemic
influenza A (H1N1) virus was defined as a person
with high fever (≥38 °C) and/or at least 2 acute
respiratory symptoms with epidemiological criteria
listed in the case definition protocol published by
WHO (8). The hospital provides medical services to
a population of 953,000 inhabitants, mainly a lowincome community.

Since the first tourist-imported case in Turkey on
16 May 2009, pandemic influenza A (H1N1) virus
has spread throughout the country, affecting mainly
young adults and children. In this article, we present
our experience with children hospitalized due to
pandemic influenza A (H1N1) virus infection. Our
aim was to describe the demographic characteristics,
clinical features, and markers of disease severity in
children with pandemic influenza A (H1N1) virus
infection. Our secondary aim was to identify risk
factors for severe disease or poor outcome.
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We used a questionnaire addressing demographic
factors (age, sex, weight, height, and underlying
medical conditions), information about a possible
epidemiological link to a pandemic influenza A
(H1N1) virus case, and clinical signs and symptoms.
Underlying CRDs were further investigated. The
diagnosis of asthma was made by a history of
intermittent wheezing and the presence of reversible
airway obstruction as defined by at least a 12%
improvement in forced expiratory volume in 1 s
(FEV1) following bronchodilator administration
and therapeutic response to antiinflammatory
medications according to international guidelines
(GINA). The diagnoses of bronchopulmonary
dysplasia and bronchiectasis were made by computed
tomography of the lung. We noted laboratory test
results, radiographic findings, treatments, and
follow-up periods. The chest X-rays of the patients
were evaluated by a radiologist who was blinded to
the history and clinical evaluation of the patients.
We did not include children admitted more than 3
days before the onset of influenza-like symptoms,
since the disease was considered incidental to their
admission.
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Respiratory samples (nasopharyngeal and nasal
swabs) were tested for pandemic influenza A (H1N1)
virus with RT-PCR at the Refik Saydam National
Public Health Agency in Ankara. The “in house” realtime RT-PCR protocol and reagents were supplied
by the Centers for Disease Control and Prevention
(Atlanta, GA, USA). The QIAamp Viral RNA Mini
Kit (QIAGEN, Valencia, CA, USA) or the High Pure
Viral RNA isolation kit (Roche Applied Science,
Penzberg, Germany) was used for RNA extraction.
Real-time RT-PCR was performed on an ABI 7000
and/or 7500 (Applied Biosystems, Foster City, CA,
USA). The NA, HA, and M genes of the index case
were partially sequenced and analyzed with CLC
Main Workbench Software 4.1.1 (CLCbio, Aarhus,
Denmark).
Oseltamivir was used as antiviral therapy in ageappropriate doses. The study was approved by the
Local Ethics Committee of the Ankara Training and
Research Hospital.
All data analyses were conducted using SPSS
for Windows, version 15 (SPSS Inc., Chicago,
IL, USA). We compared the categorical variables
using the chi-square test and the others using the
nonparametric Mann-Whitney U test. We compared
the demographic characteristics of patients with
or without chronic lung disease. Binary logistic
regression was used to determine risk factors
associated with an increased hospitalization period.
Variables that were associated with the outcomes in
the univariate analysis at a P-value of less than 0.25
were examined in the multivariate logistic regression
models. A forward likelihood ratio (LR) modeling
strategy was used. The effect of the risk factors
was measured using odds ratios (ORs) and 95%
confidence intervals (CIs). A value of P < 0.05 was
considered statistically significant.
Results
During the period of October-December 2009,
there were 126 (63.5% males) confirmed patients
with pandemic influenza A (H1N1) virus infection
hospitalized at our institution. The median
age of patients was 3 years (range: 0.1-9 years).
Nasopharyngeal swabs of 2 neonates presenting with
fever were positive for pandemic influenza A (H1N1)
virus.

The sources of the pandemic influenza A (H1N1)
virus infections were diverse, including family
history of influenza-like illness in 41.3%, nosocomial
infection in 3.2%, and travel abroad in 1.6% of the
patients.
Fever or history of fever (95.2%), cough (84.1%),
rhinorrhea (70%), and dyspnea (63.5%) were the most
common presenting symptoms of infection (Table
1). Convulsions were seen in 14 patients (11.1%),
including febrile seizures (8.3%). A diagnostic workup was done for 3 patients, and central nervous
system imaging and cerebrospinal fluid analysis
were within normal limits. All patients with seizures
recovered fully and had no neurologic sequelae at
discharge.
In the study population, growth percentiles were
within the 5th to 95th percentiles except in 1 child
aged 6 years and diagnosed with infantile spasm, for
which systemic corticosteroid had been used for the
last 3 months. The physical examinations revealed
a median respiratory rate of 34 (30-40)/min and a
median heart rate of 127 (110-138)/min. The main
findings in the respiratory system were wheezing
(24.6%), crackles (41.3%), and both wheezing and
crackles (11.3%). Respiratory distress in the form
of tachypnea (respiratory rate > 2 SD of age-specific
normal limits) and suprasternal, intercostal, and
subcostal retractions was detected in 80 (63.5%)
children.
Table 1. Symptoms at admission in children with pandemic
influenza A (H1N1) virus (n = 126).
Number of cases

%

Fever

120

95.2

Cough

106

84.1

Rhinorrhea

88

70.0

Dyspnea

80

63.5

Sore throat

35

27.8

Headache

35

27.8

Myalgia

24

19.0

Vomiting

17

13.5

Seizures

14

11.0

Diarrhea

6

4.8

Abdominal pain

5

4.0
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A total of 46 patients (36.5%) had chronic
underlying medical conditions (Table 2). CRDs
[23.4%; asthma (n = 27), bronchopulmonary
dysplasia (n = 2), and bronchiectasis (n = 1)] were
the most common accompanying chronic diseases,
followed by neurologic diseases [6.4%; cerebral palsy
(n = 5), meningomyelocele (n = 1), hydrocephaly
(n = 1), and Duchenne muscular dystrophy (n = 1)]
and cardiovascular diseases [3.1%; congenital heart
diseases (n = 3) and acute rheumatic fever (n = 1)].
In the laboratory evaluation, the median white
blood cell count was 9000 (6200-11,900)/μL,
hemoglobin concentration 12.0 (11.2-13.0) g/dL,
and erythrocyte sedimentation rate 14 (5.5-27.5)/h.
Chest radiography was done on 96 patients, and 25
of them were normal. The main radiologic findings
were interstitial infiltration (n = 28), hilar lymph node
enlargement (n = 19), and lobar consolidation (n = 5).
When patients were grouped based on the
presence of CRD, patients with CRD were older than
those without CRD [median age of 6 (3-10) years
vs. 2 (0.1-7) years, respectively; P = 0.003] (Table 3).
Even though the onset of symptoms before admission

did not differ between groups, physical examination
findings differed in the respiratory system. Crackles
alone were observed in children without CRD, while
wheezing was most commonly seen in patients with
CRD. Respiratory distress was more prominent in
children with CRD compared to children without
CRD [29 (96.7%) vs. 51 (63.8%), respectively; P <
0.001], but chest X-ray findings were similar (data not
shown). During the hospitalization period, durations
of oxygen requirement and wheezing were longer in
patients with CRD.
The median time from onset of illness to antiviral
treatment was 2 days (range: 1-13). Oseltamivir was
used as antiviral therapy after respiratory samples were
taken in all patients and it influenced the morbidity
of the pandemic influenza A (H1N1) virus infection
(Table 4). The duration of oxygen requirement and
tachypnea decreased if oseltamivir was initiated
within 48 h of the onset of symptoms compared to
patients whose therapy was initiated ≥48 hours after
onset (P = 0.006 and 0.033, respectively). In 15% of
patients, side effects due to oseltamivir were observed
as diarrhea (13.5%) and vomiting (1.6%).

Table 2. Underlying medical conditions of the patients.
n (%)
Chronic respiratory disease
Asthma
(Asthma + idiopathic thrombocytopenic purpura)
Bronchopulmonary dysplasia
Bronchiectasis

2 (1.6)
1 (0.8)

Neurologic disease
Cerebral palsy
Meningomyelocele
Hydrocephaly
Duchenne muscular dystrophy

8 (6.4)
5 (4.0)
1 (0.8)
1 (0.8)
1 (0.8)

Cardiovascular disease
Congenital heart diseases
Acute rheumatic fever

4 (3.1)
3 (2.3)
1 (0.8)

Diabetes mellitus

1 (0.8)

Fructose intolerance

1 (0.8)

Henoch-Schönlein purpura

1 (0.8)

Mucopolysaccharidosis
Total
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30 (23.8)
27 (21.4)

1 (0.8)
46 (36.5)
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Table 3. Demographic, clinical, and laboratory features of patients with and without chronic respiratory disease.

Whole group
(n = 126)

Chronic respiratory
disease (+)
(n = 30)

Chronic
respiratory
disease (-)
(n = 96)

P

Age (years)*

3 (0.1-9)

6 (3-10)

2 (1-7)

0.003

Sex (male) (%)

80 (63.5)

18 (60)

62 (64.6)

>0.05

Onset of symptoms (days)*

2 (1-2)

2 (1-3)

1.5 (1-2)

>0.05

Influenza vaccination, current season (%)

8 (6.3)

6 (20)

2 (2.1)

<0.001

Fever (%)

120 (95.2)

28 (93.3)

92 (95.8)

>0.05

Cough (%)

106 (84.1)

28 (93.3)

78 (81.3)

>0.05

34 (30-40)

32 (30-36)

36 (30-40)

>0.05

127 (110-138)

121 (102-138)

128 (114-138)

>0.05

Crackles (%)

52 (41.3)

-

52 (54.2)

<0.001

Wheezing (%)

31 (24.6)

23(76.7)

8 (8.3)

<0.001

Crackles + wheezing (%)

14 (11.1)

7(23.3)

7(7.3)

<0.001

Respiratory distress (%)

80 (63.5)

29 (96.7)

51 (53.1)

<0.001

6 (4.8)

2 (6.7)

4 (4.2)

>0.05

Total leukocyte count (×10 /L)*

9 (6.2-11.9)

6.7 (4.8-12)

9.2 (6.7-11.9)

>0.05

Erythrocyte sedimentation rate (mm/h)*

14 (5.5-27.5)

9 (2-18)

15.5 (7-33)

0.026

2 (0-3)

3 (2-4)

0 (0-3)

<0.001

Duration of tachypnea (days)*

2 (1.5-4)

2 (2-3.5)

2 (1-4)

>0.05

Duration of wheezing (days)*

2 (0-4)

3 (2-5)

1 (0-3)

0.007

Duration of hospitalization (days)*

4 (3-6)

4 (3-6)

4 (3-5)

>0.05

Physical examination
Respiratory rate/min*
Heart rate/min*

Respiratory insufficiency (%)
3

Follow-up period
Duration of O2 requirement (days)*

*median (interquartile range)

Table 4. The effect of initiation of antiviral therapy on morbidity.
<48 hours

≥48 hours

P

1 (0-3.0)

3 (1.5-4.0)

0.006

Duration of tachypnea (days)*

1.5 (0.3-3.0)

2 (2.0-3.8)

0.033

Duration of wheezing (days)*

2 (0-3.0)

3 (0-5.0)

>0.05

4 (3.0-5.3)

4.5 (4.0-6.0)

>0.05

Duration of O2 requirement (days)*

Duration of hospitalization (days)*
*median (interquartile range)
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The median time of hospitalization was 4 (range:
3-6) days. Logistic regression analysis was done to
determine risk factors associated with hospitalization
of ≥4 days. Sex, respiratory distress at admission,
concomitant chronic disease, concomitant CRD,
smoke exposure, and initiation of antiviral therapy
within 48 h of onset of symptoms were included in
the regression model. None of these factors were
associated with longer hospitalization periods.
Our 2 patients with severe chronic neurologic
disease died. A 16-year-old boy with Duchenne
muscular dystrophy was diagnosed with pandemic
influenza A (H1N1) virus infection and pneumonia.
He was treated with oseltamivir and ceftriaxone for
5 days and he needed mechanical ventilation. Due
to the increased severity of his respiratory distress,
he died 20 days after hospitalization. A 15-monthold girl with hydrocephalus, a ventriculoperitoneal
shunt, and growth retardation was admitted due
to cough and fever over the previous 10 days and
was diagnosed with pandemic influenza A (H1N1)
virus infection and pneumonia. She was treated with
oseltamivir and ceftriaxone for 7 days. Due to the
increased severity of her respiratory distress and the
expanded infiltration revealed in a chest X-ray on day
8, her antibiotic regimen was changed to imipenem
and vancomycin, but she did not recover and died on
the same day.
Discussion
In 2009, the H1N1 influenza virus caused a pandemic,
creating public apprehension and a socioeconomic
burden, especially on health care systems. This
necessitated the sharing of experiences in different
countries during this pandemic with emphasis
on severe/hospitalized patients. In this study, we
reviewed our patients with pandemic influenza A
(H1N1) virus infection hospitalized in a tertiary care
center, which also served as a primary and secondary
care facility during the pandemic.
The rate of hospital admission due to pandemic
influenza A (H1N1) virus was highest among
children less than 5 years old in both Chicago
and New York (9,10). In Canada, the mean age of
children hospitalized because of pandemic influenza
A (H1N1) was 6.4 years, versus 3.3 years because of
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seasonal influenza. We observed that our hospitalized
patients with the pandemic influenza A (H1N1)
virus were younger compared to the Canadian data
(11). However, community epidemiologic data
are essential to assist in interpreting the observed
difference in the ages of children admitted to hospital.
Recent data support the development of
neurological complications in children in association
with the pandemic influenza A (H1N1) virus
in the United States. In the United States, it was
reported that the H1N1 influenza virus caused acute
encephalopathy and encephalitis without leading
to mortality and sequelae (7). Convulsions with or
without fever were seen as a presenting symptom
in 11% of our patients. The incidence rate of
gastrointestinal symptoms such as diarrhea among
confirmed cases in children was found to be 23%. The
frequency of diarrhea ranged from 17% in Cyprus to
36% in Canada and 42% in the United States (11-13).
Because all of our patients were hospitalized,
compliance with oseltamivir treatment was high
(100%). Furthermore, side effects, seen in 15% of all
cases, were nausea and vomiting, the most common
side effects reported in the literature (14,15). In a
recent study on school-aged children in the United
Kingdom, in which children received oseltamivir as
influenza prophylaxis, the rate of adverse effects was
much higher, with 40% of the students developing
gastrointestinal symptoms and 18% developing
mild neuropsychiatric side effects such as poor
concentration, sleeping problems, bad dreams,
and strange behavior (16). No patient in our series
presented any of the neuropsychiatric side effects
described in that report. This might be attributed
to the younger age of the subjects in our study, who
may have been unable to express their complaints
properly.
Asthma has been identified as a significant risk
factor for the pandemic influenza A (H1N1) virus
requiring hospital admission, present at 21%-30% in
other studies (9,10). Surveillance for pediatric deaths
associated with the pandemic influenza A (H1N1)
virus in the United States declared that asthma or
reactive airway disease was a part of the underlying
condition in only 3 of 36 children who died of
pandemic influenza A (H1N1) virus. Furthermore,
all of these children also had neurologic impairment
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(17). Our experience suggested that asthma
was a more significant risk factor for pandemic
influenza A (H1N1) virus infection requiring
hospitalization (21.4%). O’Riordan et al. stated that
even mild persistent asthma could be a risk factor for
hospitalization due to pandemic influenza A (H1N1)
virus infection, and the risk was also higher compared
to infection with a seasonal influenza virus (11).
Furthermore, they reported that more than 50%
of the children with asthma admitted to their hospital
for pandemic influenza A (H1N1) virus infection
presented with evidence of pneumonia, with or
without bronchospasm, compared to those admitted
for seasonal influenza. We cannot estimate the rate
of admission to the hospital because of pandemic
influenza A (H1N1) virus without population-based
epidemiologic data. This is an area for imminent
future research.
CRD and neurodevelopmental disorders were the
most commonly reported conditions in a national
survey investigating mortality due to pandemic
influenza A (H1N1) virus infection in England.
The median age of patients was 8 (range: 2-19, n =
25) in those with neurodevelopmental disorders.
As age increased, asthma and chronic obstructive
respiratory disease were the major risk factors for
mortality (18). Our 2 patients with severe chronic
neurologic disease died.

Delays in the prescription of antiviral drugs
emerged from studies of hospitalized patients in the
United States and England (13,18). An analysis of 272
inpatients with pandemic influenza A (H1N1) virus
infection in the United States suggested that use of
antiviral drugs confers a survival benefit, particularly
when they are started within 2 days of the onset of
illness (13). In England, antiviral treatment was given
within 48 h of the onset of symptoms in only 9% of
patients and delayed treatment led to an increase
in mortality (18). However, in another study in the
United States, the duration of critical illness did not
differ between early- and late-onset treatment groups
(19). In this study, we showed that antiviral treatment
within 48 h of disease onset decreased morbidity in
terms of the durations of oxygen requirement and
tachypnea.
In our cohort, the pandemic influenza A (H1N1)
virus infection did not appear to cause severe disease,
and the majority of pediatric cases had a mild
clinical course. Treatment with antivirals appeared
to not have any major adverse effects. Asthma was
a significant risk factor for severe disease among
children with pandemic influenza A (H1N1) virus.
Delayed (≥48 h) initiation of antiviral therapy might
have contributed to an increase in morbidity, which
suggests the importance of timely administration of
antiviral treatments.
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